The Yet Unrealized Promise of Ovarian Cancer Screening
References
1.
US
Preventive Services Task Force. Screening for ovarian cancer: US
Preventive Services Task Force recommendation statement [published
February 13, 2018]. JAMA. doi:10.1001/jama.2017.21926Google Scholar
2.
Henderson
JT, Webber
EM, Sawaya
GF. Screening for ovarian cancer: updated evidence report and
systematic review for the US Preventive Services Task Force [published
February 13, 2018]. JAMA. doi:10.1001/jama.2017.21421Google Scholar
3.
Jacobs
IJ, Menon
U, Ryan
A,
et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet. 2016;387(10022):945-956.PubMedGoogle ScholarCrossref
4.
Buys
SS, Partridge
E, Black
A,
et al; PLCO Project Team. Effect of screening on ovarian cancer
mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer
screening randomized controlled trial. JAMA. 2011;305(22):2295-2303.PubMedGoogle ScholarCrossref
5.
Jacobs
IJ, Skates
SJ, MacDonald
N,
et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet. 1999;353(9160):1207-1210.PubMedGoogle ScholarCrossref
6.
Barrett
J, Jenkins
V, Farewell
V,
et al; UKCTOCS trialists. Psychological morbidity associated with
ovarian cancer screening: results from more than 23,000 women in the
randomised trial of ovarian cancer screening (UKCTOCS). BJOG. 2014;121(9):1071-1079.PubMedGoogle ScholarCrossref
7.
American
College of Obstetricians and Gynecologists (ACOG) Committee on
Gynecologic Practice; Society of Gynecologic Oncology. ACOG Committee
opinion No. 716, September 2017. https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Gynecologic-Practice/The-Role-of-the-Obstetrician-Gynecologist-in-the-Early-Detection-of-Epithelial-Ovarian-Cancer-in. Accessed January 22, 2018.
8.
Marchetti
C, De Felice
F, Palaia
I,
et al. Risk-reducing salpingo-oophorectomy: a meta-analysis on
impact on ovarian cancer risk and all-cause mortality in BRCA 1 and BRCA
2 mutation carriers. BMC Womens Health. 2014;14:150.PubMedGoogle ScholarCrossref
9.
Rosenthal
AN, Fraser
LSM, Philpott
S,
et al; United Kingdom Familial Ovarian Cancer Screening Study
collaborators. Evidence of stage shift in women diagnosed with ovarian
cancer during phase II of the UK Familial Ovarian Cancer Screening
Study. J Clin Oncol. 2017;35(13):1411-1420.PubMedGoogle ScholarCrossref
10.
Skates
SJ, Greene
MH, Buys
SS,
et al. Early detection of ovarian cancer using the Risk of Ovarian
Cancer Algorithm with frequent CA125 testing in women at increased
familial risk. Clin Cancer Res. 2017;23(14):3628-3637.PubMedGoogle ScholarCrossref
11.
Karlan
BY, Thorpe
J, Watabayashi
K,
et al. Use of CA125 and HE4 serum markers to predict ovarian cancer in elevated-risk women. Cancer Epidemiol Biomarkers Prev. 2014;23(7):1383-1393.PubMedGoogle ScholarCrossref
12.
Menon
U, McGuire
AJ, Raikou
M,
et al. The cost-effectiveness of screening for ovarian cancer:
results from the UK Collaborative Trial of Ovarian Cancer Screening
(UKCTOCS). Br J Cancer. 2017;117(5):619-627.PubMedGoogle ScholarCrossref
13.
Sieh
W, Salvador
S, McGuire
V,
et al; Australian Cancer Study (Ovarian Cancer); Australian Ovarian
Cancer Study Group; Ovarian Cancer Association Consortium. Tubal
ligation and risk of ovarian cancer subtypes. Int J Epidemiol. 2013;42(2):579-589.PubMedGoogle ScholarCrossref
14.
Garcia
C, Martin
M, Tucker
LY,
et al. Experience with opportunistic salpingectomy in a large, community-based health system in the United States. Obstet Gynecol. 2016;128(2):277-283.PubMedGoogle ScholarCrossref
15.
Powell
CB, Swisher
EM, Cass
I,
et al. Long-term follow-up of BRCA1 and BRCA2 mutation carriers
with unsuspected neoplasia identified at risk reducing
salpingo-oophorectomy. Gynecol Oncol. 2013;129(2):364-371.PubMedGoogle ScholarCrossref
16.
Labidi-Galy
SI, Papp
E, Hallberg
D,
et al. High grade serous ovarian carcinomas originate in the fallopian tube. Nat Commun. 2017;8(1):1093.PubMedGoogle ScholarCrossref